Artificial intelligence (AI) software developer Viz.ai has secured de novo approval by the U.S. Food and Drug Administration (FDA) for its cardiomyopathy AI detection algorithm.
Integrated into the Viz.ai Platform, the algorithm automatically reviews routine electrocardiograms, which can help with coordinating follow-up echocardiography exams for diagnosis and using the Viz Echo Viewer to review images and access echocardiogram reports, according to the vendor.
The company said the deployment of the algorithm is financially supported by a multiyear agreement with Bristol Myers Squibb, announced in March.
